Specifically, in subjects who experienced a reduction of NAFLD severity, plasma concentrations of GDF15 decreased, while, in those in whom the disease progressed, plasma concentrations of GDF15 increased significantly. The gene discussed is GDF15; the disease is metabolic dysfunction-associated steatotic liver disease.